Bicara Therapeutics executive exercises options, sells shares

Rhea-AI Filing Summary

Bicara Therapeutics Inc. President and COO Ryan Cohlhepp reported an option exercise and same‑day share sale in Bicara Therapeutics Inc. On 2026-08-10 he exercised 18,750 stock options at an exercise price of $3.7898 per share, receiving 18,750 shares of common stock. The same day, he sold 18,750 common shares at a weighted average price of $27.9751 per share, with individual sale prices ranging from $27.56 to $28.41, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Following the derivative transaction, 51,752 stock options remained reported outstanding, expiring on 2033-04-05, from a grant that vests in sixteen equal quarterly installments after April 5, 2023, subject to continued service.

Insider Trade Summary 10b5-1

Exercise and Sale: 18,750 shares ($453K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Cohlhepp Ryan

Role President and COO

Sold 18,750 shs ($525K)

Approx. gross sale proceeds $525K

Approx. exercise cost $71K

Approx. pre-tax spread $453K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	18,750	$0.00	$0.00
Exercise	Common Stock F1	18,750	$3.7898	$71K
Sale	Common Stock F1, F2	18,750	$27.9751	$525K

Holdings After Transaction: Stock Option (Right to Buy) — 51,752 contracts (Direct); Common Stock — 181,641 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.56 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. F3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Options exercised: 18,750 shares Exercise price: $3.7898 per share Shares sold: 18,750 shares +4 more

7 metrics

Options exercised 18,750 shares Stock options exercised into common stock on 2026-08-10

Exercise price $3.7898 per share Exercise price of stock options converted to common stock

Shares sold 18,750 shares Common stock sold on 2026-08-10

Weighted average sale price $27.9751 per share Weighted average price for shares sold, with trades from $27.56 to $28.41

Remaining options 51,752 options Stock options reported following the derivative transaction

Option expiration 2033-04-05 Expiration date of the option grant involved in the exercise

10b5-1 plan adoption date March 31, 2026 Date the Rule 10b5-1 trading plan governing these trades was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vesting financial

"shares underlying this option vest in sixteen equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bicara Therapeutics (BCAX) President and COO Ryan Cohlhepp report on this Form 4?

Ryan Cohlhepp exercised 18,750 stock options at $3.7898 per share and sold 18,750 common shares at a weighted average price of $27.9751 on 2026-08-10, all as reported in this Form 4.

How many Bicara Therapeutics (BCAX) options did Ryan Cohlhepp exercise and at what price?

He exercised 18,750 stock options for Bicara Therapeutics common stock at an exercise price of $3.7898 per share on 2026-08-10, converting them into an equal number of common shares.

What price did Ryan Cohlhepp receive for the Bicara Therapeutics (BCAX) shares he sold?

He sold 18,750 common shares at a weighted average price of $27.9751 per share, with individual sale prices ranging from $27.56 to $28.41, as disclosed in the footnotes.

Was the Bicara Therapeutics (BCAX) insider transaction under a Rule 10b5-1 plan?

Yes. The transactions were executed pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2026, according to the referenced footnote.

How many Bicara Therapeutics (BCAX) options does Ryan Cohlhepp report remaining after this transaction?

Following the reported option exercise, he reports 51,752 stock options outstanding, with an expiration date of 2033-04-05, linked to a grant vesting in sixteen equal quarterly installments.

What are the vesting terms of the Bicara Therapeutics (BCAX) options involved in this Form 4?

The options underlying this transaction vest in sixteen equal quarterly installments after April 5, 2023, and vesting is subject to Ryan Cohlhepp’s continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 04:19 PM Accepted by SEC EDGAR 08/12/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohlhepp Ryan

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		M(1)		18,750	A	$3.7898	200,391	D
Common Stock	08/10/2026		S(1)		18,750	D	$27.9751(2)	181,641	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7898	08/10/2026		M(1)			18,750	(3)	04/05/2033	Common Stock	18,750	$0	51,752	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.56 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Ryan Cohlhepp	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)